LeMaitre Vascular, Inc. filings document a Nasdaq-listed medical device company focused on vascular devices, implants, and services for peripheral vascular disease. Recent Form 8-K reports furnish quarterly operating and financial results, dividend-related updates, and related press release exhibits.
Proxy and governance filings cover board structure, director elections, executive compensation, advisory say-on-pay matters, and shareholder voting results. The filings also identify the company’s common stock, par value, Nasdaq Global Market listing under LMAT, and related public-company disclosure controls.
On Form 144, insider George W. LeMaitre filed notice to sell 100,000 common shares of LeMaitre Vascular Inc. (LMAT) through Charles Schwab on or about 6 Aug 2025. At the referenced price, the block is valued at $9.35 million and represents roughly 0.44 % of the 22.64 million shares outstanding.
The filing also lists three prior sales by the same holder between 16–20 May 2025 totaling 100,000 shares for $10.71 million in gross proceeds. The shares being disposed of were originally acquired on 2 Jun 1997 via a promissory-note transaction.
No operational or financial results are provided; the document strictly satisfies Rule 144 disclosure requirements. Nevertheless, the continued insider dispositions may create a modest share-supply overhang and could be interpreted as a signal of profit-taking ahead of the August execution date.